Kate E. Creevy
Runs the veterinary side of the Dog Aging Project and leads TRIAD, the trial testing whether rapamycin extends lifespan in pet dogs
Professor of Small Animal Internal Medicine, Texas A&M University College of Veterinary Medicine & Biomedical Sciences · Chief Veterinary Officer and scientific founder, Dog Aging Project · DVM, University of Tennessee · MS, University of Georgia · Diplomate, ACVIM (Small Animal Internal Medicine)
Portrait: AVMA
Kate Creevy is a veterinary internist who studies why some dogs live longer and healthier lives than others. As chief veterinary officer and a scientific founder of the Dog Aging Project, she helped set up the veterinary protocols and national infrastructure for a long-running study that has enrolled more than 50,000 companion dogs and shares its data openly with researchers.
Pet dogs live in our homes, share our environment and age much faster than we do, which makes them a practical test bed for ideas from mTOR biology. Creevy is senior author of a 2023 placebo-controlled trial of six months of low-dose rapamycin in 17 healthy dogs, which found no clinically significant adverse events but also no significant change in heart function, and she leads TRIAD, a multicentre trial that will test whether rapamycin extends lifespan in middle-aged dogs. In 2026 the American Veterinary Medical Association gave her its Career Achievement in Canine Research Award.
The timeline below follows Creevy's contributions gathered in this Atlas.
Milestones in the Atlas
A selection, not a full bibliography: only papers that meet the Atlas inclusion criteria.
| Year | Evidence | Study |
|---|---|---|
| 2023 | A | A masked, placebo-controlled, randomized clinical trial evaluating safety and the effect on cardiac function of low-dose rapamycin in 17 healthy client-owned dogs BAR2023 Senior author of a placebo-controlled six-month trial of low-dose rapamycin in 17 healthy dogs: well tolerated, but no significant change in heart function. |
| 2025 | RT | Test of Rapamycin in Aging Dogs (TRIAD): study design and rationale for a prospective, parallel-group, double-masked, randomized, placebo-controlled, multicenter trial of rapamycin in healthy middle-aged dogs from the Dog Aging Project COL2025 Co-author of the design paper for TRIAD, the first placebo-controlled lifespan trial of rapamycin outside the laboratory, which she leads; no results yet. |
Co-authors in the Atlas
People with a profile here who share at least one study with Kate E. Creevy.
- Matt Kaeberlein 2 shared studies Extended TOR/aging research from yeast to mice to pet dogs
- Amanda Erickson Coleman Veterinary cardiologist and first author of the design paper for TRIAD, the lifespan trial of rapamycin in pet dogs
- Brian G. Barnett First author of the six-month, placebo-controlled trial of low-dose rapamycin in healthy pet dogs
Every researcher with a profile →
Thank you. Your answer was counted anonymously.
Thank you. That helps us know which pages have been read by someone who knows the work.
Thank you. We will check it and correct the page.